Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Total Debt: 2020-2023

Historic Total Debt for C4 Therapeutics (CCCC) over the last 2 years, with Jun 2023 value amounting to $10.3 million.

  • C4 Therapeutics' Total Debt fell 7.08% to $10.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $10.3 million, marking a year-over-year decrease of 7.08%. This contributed to the annual value of $11.5 million for FY2022, which is 6.63% up from last year.
  • C4 Therapeutics' Total Debt amounted to $10.3 million in Q2 2023, which was down 5.25% from $10.9 million recorded in Q1 2023.
  • In the past 5 years, C4 Therapeutics' Total Debt ranged from a high of $11.5 million in Q4 2022 and a low of $9.9 million during Q3 2020.
  • Its 3-year average for Total Debt is $10.8 million, with a median of $10.8 million in 2021.
  • In the last 5 years, C4 Therapeutics' Total Debt grew by 7.20% in 2021 and then fell by 7.08% in 2023.
  • Over the past 4 years, C4 Therapeutics' Total Debt (Quarterly) stood at $10.1 million in 2020, then climbed by 7.12% to $10.8 million in 2021, then climbed by 6.63% to $11.5 million in 2022, then decreased by 7.08% to $10.3 million in 2023.
  • Its Total Debt stands at $10.3 million for Q2 2023, versus $10.9 million for Q1 2023 and $11.5 million for Q4 2022.